CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 6 enrolled
Drug / intervention
Video Assisted Speech Therapy (VAST)behavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04764539
NCT04764539N/ACompleted

Video Assisted Speech Technology to Enhance Functional Language Abilities in Individuals With Autism Spectrum Disorder

iTherapy, LLC·interventional·Posted Feb 21, 2021·Updated May 9, 2023

In Brief

A clinical study evaluating Video Assisted Speech Therapy (VAST) for Autism Spectrum Disorder and Apraxia of Speech. Completed, enrolled 6 participants across 1 site.

Detailed Summary

Nearly 3.5 million Americans are diagnosed with Autistic Spectrum Disorder (ASD), a communication disorder that causes skill limitations in the areas of language acquisition, sensory integration, and behavior. This lack of functional language ability limits conversation to its most basic parts, making daily tasks difficult for minimally to non-verbal individuals to achieve. iTherapy is developing the VAST platform, a personalized educational experience for students with ASD by creating a virtual reality-based video-modeling program to stimulate engagement and speech production practice, ultimately providing those with ASD an opportunity to enhance their quality of life by increasing their speech abilities which will enable them to build social networks and handle the events of daily life.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedFeb 21, 2021
Enrollment StartDec 1, 2019
Primary CompletionNov 30, 2020
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 5.4 years ago

Interventions

Video Assisted Speech Therapy (VAST)behavioral

Six children with ASD, between the ages of 4 and 8, participated in a 14-sessions-long study that utilized the VR-integrated and the tablet-based VAST application. Three subjects received a 3D VR-integrated, bone conduction VAST prototype, while the remaining group of three received a tablet with a 2D version of the software. Sessions were held twice a week with each lasting approximately 15 minutes (i.e. +/- 5 minutes).